<DOC>
	<DOCNO>NCT02650817</DOCNO>
	<brief_summary>The purpose study visualize quantify ER-binding site treatment RAD1901</brief_summary>
	<brief_title>A Phase IB Study Evaluate Effect RAD1901 Availability Estrogen Receptor Binding Sites Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Key 1 . Patients histologicallyproven , ERpositive , human epidermal growth factor receptor 2 ( HER2 ) negative , locally advanced , inoperative , and/or mBC 2 . Tumor progression â‰¥ 6 month least 1 line hormonal systemic treatment ( SERM , SERD , aromatase inhibitor ) metastatic set 3 . Measurable disease accord RECIST criterion v1.1 clinically evaluable disease 4 . Greater equal 18 year age 5 . Patients must postmenopausal 6 . Life expectancy &gt; 3 month Key 1 . Prior anticancer treatment investigational drug therapy within follow window : 1 . Tamoxifen fulvestrant therapy &lt; 42 day 1st 18FESPET scan 2 . Any anticancer endocrine therapy &lt; 14 day 1st dose study drug 3 . Any chemotherapy &lt; 28 day 1st dose study drug 4 . Any investigational drug therapy &lt; 28 day 3 halflives ( whichever longer ) prior 1st dose study drug 2 . Patients symptomatic central nervous system ( brain ) metastases 3 . Patients know endometrial disorder , include evidence endometrial hyperplasia , dysfunctional uterine bleeding , cyst</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>